Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 9,067 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the transaction, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $2,779,659.78. This represents a 9.01% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.79, for a total transaction of $306,475.30.
• On Monday, December 22nd, Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.
• On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The stock was sold at an average price of $36.81, for a total value of $853,513.47.

Hims & Hers Health Price Performance

NYSE:HIMS traded down $1.64 during trading hours on Wednesday, reaching $28.83. 27,825,825 shares of the company were exchanged, compared to its average volume of 17,159,578. The company has a market capitalization of $6.56 billion, a P/E ratio of 53.39, a P/E/G ratio of 5.32 and a beta of 2.37. The business has a 50 day moving average of $35.41 and a 200 day moving average of $45.43. Hims & Hers Health, Inc. has a 1-year low of $23.97 and a 1-year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million during the quarter, compared to analyst estimates of $578.99 million. During the same quarter in the previous year, the business posted $0.32 earnings per share. The company’s revenue for the quarter was up 49.2% on a year-over-year basis. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health announced that its board has authorized a stock repurchase plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to purchase up to 3% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after buying an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Hims & Hers Health during the first quarter valued at approximately $30,000. Parallel Advisors LLC increased its holdings in shares of Hims & Hers Health by 175.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,155 shares of the company’s stock valued at $58,000 after acquiring an additional 735 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Hims & Hers Health by 24.2% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 15,638 shares of the company’s stock valued at $750,000 after purchasing an additional 3,050 shares in the last quarter. Finally, UMB Bank n.a. boosted its holdings in shares of Hims & Hers Health by 87.3% in the 2nd quarter. UMB Bank n.a. now owns 2,453 shares of the company’s stock valued at $122,000 after buying an additional 1,143 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently commented on HIMS. KeyCorp started coverage on Hims & Hers Health in a research report on Tuesday, October 21st. They set a “sector weight” rating for the company. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday. Evercore ISI initiated coverage on shares of Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target on the stock. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $44.54.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.